For example, the JUPITER trial demonstrated that rosuvastatin significantly reduced high-sensitivity C-reactive protein (hs-CRP) levels [6], a marker of inflammation, while the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial observed a reduction in inflammatory biomarkers in heart failure patients treated with rosuvastatin [8]. This evidence concerns the gene CRP and heart failure.